Agreements Support the Upcoming Launch of VEVYE®NASHVILLE, Tenn.--(BUSINESS WIRE)--$HROW--Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that...
Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment...
– Results published in JACI: In Practice show rapid and sustained reductions in HAE attacks and improved quality of life...
- Stanford Medicine, a center with a long tradition of leadership in pioneering gynecological research and innovation, is the second...
Program reaches 12,000 Medicaid-eligible families Michigan-specific content viewed over 850,000 times in the first year Michigan expanding access to premium...
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence...
Health Care Service Corporation, Laerdal Million Lives Fund, BayCare, Parkview Health, University of Chicago Medicine, Organon and Stryker to support...
BOSTON, MA / ACCESSWIRE / December 5, 2023 / The Epilepsy & Pregnancy Medical Consortium (EPMC), an expert panel of...
Ovaprene has the Potential to be the First FDA-Approved Monthly, Self-Administered, Hormone-Free Contraceptive ProductSAN DIEGO, Dec. 04, 2023 (GLOBE NEWSWIRE)...
CALQUENCE six-year follow-up data reinforce long-term benefit in chronic lymphocytic leukemia, and data across multiple hematology assets showcase breadth of...
RESEARCH TRIANGLE PARK, N.C., Nov. 29, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the National Administration...
- Topline results from FemaSeed® pivotal trial expected in 1H 2024 - - Commercial launch planned for early 2024 -...
GAITHERSBURG, Md., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that the Biomedical Advanced Research...
These Frontline workers deserve a monument, Please donate $10 to honor them today! Casey Schachner COVID-19 Monument Design Contest winner...
New eClinicalWorks AI assistant tools are improving patient satisfaction and care with multi-language supportWESTBOROUGH, Mass.--(BUSINESS WIRE)--eClinicalWorks®, the largest ambulatory cloud...
Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS target...
Conference Call and Webcast Today at 4:30 p.m. ET What to Expect for the Remainder of 2023 XACIATO™: receipt of...
Company Introduces Multimedia Resources to Bring Awareness of SADLAVAL, QC / ACCESSWIRE / November 8, 2023 / As daylight saving...
Two late-breaking high-impact oral presentations of the Phase 3 PROTECT Study of FILSPARI®(sparsentan) in IgAN and Phase 3 DUPLEX Study...
Studies address cost-effectiveness and budget impact of INPEFA, an inhibitor of SGLT2 and SGLT1 INPEFA recently approved by FDA for treatment...